Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Feb;82(4):905–912. doi: 10.1054/bjoc.1999.1018

Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumourcells

A Di Paolo 1, R Danesi 1, D Nardini 1, G Bocci 1, F Innocenti 1, S Fogli 1, S Barachini 1, A Marchetti 2, G Bevilacqua 2, M Del Tacca 1
PMCID: PMC2374379  PMID: 10732765

Abstract

The aim of the present study was to assess the cytotoxicity of manumycin, a specific inhibitor of farnesyl:protein transferase, as well as its effects on protein isoprenylation and kinase-dependent signal transduction in COLO320-DM human colon adenocarcinoma which harbours a wild-type K- ras gene. Immunoblot analysis of isolated cell membranes and total cellular lysates of COLO320-DM cells demonstrated that manumycin dose-dependently reduced p21 ras farnesylation with a 50% inhibitory concentration (IC50) of 2.51 ± 0.11 μM and 2.68 ± 0.20 μM, respectively, while the geranylgeranylation of p21 rhoA and p21 rap1 was not affected. Manumycin dose-dependently inhibited (IC50= 2.40 ± 0.67 μM) the phosphorylation of the mitogen-activated protein kinase/extracellular-regulated kinase 2 (p42MAPK/ERK2), the main cytoplasmic effector of p21 ras, as well as COLO320-DM cell growth (IC50= 3.58 ± 0.27 μM) without affecting the biosynthesis of cholesterol. Mevalonic acid (MVA, 100 μM), a substrate of the isoprenoid synthesis, was unable to protect COLO320-DM cells from manumycin cytotoxicity. Finally, manumycin 1–25 μM for 24–72 h induced oligonucleosomal fragmentation in a dose- and time-dependent manner and MVA did not protect COLO320-DM cells from undergoing DNA cleavage. The present findings indicate that the inhibition of p21 ras processing and signal transduction by manumycin is associated with marked inhibition of cell proliferation and apoptosis in colon cancer cells and the effect on cell growth does not require the presence of a mutated ras gene for maximal expression of chemotherapeutic activity. © 2000 Cancer Research Campaign

Keywords: manumycin, colorectal neoplasms, ras proteins, apoptosis, protein isoprenylation

Full Text

The Full Text of this article is available as a PDF (192.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bos J. L. ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep 1;49(17):4682–4689. [PubMed] [Google Scholar]
  2. Corsini A., Maggi F. M., Catapano A. L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 1995 Jan;31(1):9–27. doi: 10.1016/1043-6618(95)80042-5. [DOI] [PubMed] [Google Scholar]
  3. Cox A. D., Der C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta. 1997 Aug 8;1333(1):F51–F71. doi: 10.1016/s0304-419x(97)00011-5. [DOI] [PubMed] [Google Scholar]
  4. Danesi R., Figg W. D., Reed E., Myers C. E. Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol. 1995 Jun;47(6):1106–1111. [PubMed] [Google Scholar]
  5. Danesi R., Nardini D., Basolo F., Del Tacca M., Samid D., Myers C. E. Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacol. 1996 Jun;49(6):972–979. [PubMed] [Google Scholar]
  6. Giancotti F. G., Mainiero F. Integrin-mediated adhesion and signaling in tumorigenesis. Biochim Biophys Acta. 1994 May 27;1198(1):47–64. doi: 10.1016/0304-419x(94)90005-1. [DOI] [PubMed] [Google Scholar]
  7. Gibbs J. B., Oliff A., Kohl N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 1994 Apr 22;77(2):175–178. doi: 10.1016/0092-8674(94)90308-5. [DOI] [PubMed] [Google Scholar]
  8. Gibbs J. B., Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol. 1997;37:143–166. doi: 10.1146/annurev.pharmtox.37.1.143. [DOI] [PubMed] [Google Scholar]
  9. Hara M., Akasaka K., Akinaga S., Okabe M., Nakano H., Gomez R., Wood D., Uh M., Tamanoi F. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2281–2285. doi: 10.1073/pnas.90.6.2281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hara M., Han M. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3333–3337. doi: 10.1073/pnas.92.8.3333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ikeda M., Koyama S., Okazaki M., Dohi K., Kikuchi A. rap1 p21 regulates the interaction of ras p21 with RGL, a new effector protein of ras p21. FEBS Lett. 1995 Nov 13;375(1-2):37–40. doi: 10.1016/0014-5793(95)01169-f. [DOI] [PubMed] [Google Scholar]
  12. Kawabata H., Anzai N., Yoshida Y., Okuma M. A new method for quantitative estimation of the degree of DNA fragmentation utilizing agarose gel electrophoresis. Int J Hematol. 1994 Jun;59(4):311–316. [PubMed] [Google Scholar]
  13. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  14. Larcher F., Robles A. I., Duran H., Murillas R., Quintanilla M., Cano A., Conti C. J., Jorcano J. L. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res. 1996 Dec 1;56(23):5391–5396. [PubMed] [Google Scholar]
  15. Levitzki A. Targeting signal transduction for disease therapy. Curr Opin Cell Biol. 1996 Apr;8(2):239–244. doi: 10.1016/s0955-0674(96)80071-8. [DOI] [PubMed] [Google Scholar]
  16. Lowy D. R., Willumsen B. M. Function and regulation of ras. Annu Rev Biochem. 1993;62:851–891. doi: 10.1146/annurev.bi.62.070193.004223. [DOI] [PubMed] [Google Scholar]
  17. Maltese W. A. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 1990 Dec;4(15):3319–3328. doi: 10.1096/fasebj.4.15.2123808. [DOI] [PubMed] [Google Scholar]
  18. Marchetti A., Buttitta F., Pellegrini S., Chella A., Bertacca G., Filardo A., Tognoni V., Ferreli F., Signorini E., Angeletti C. A. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol. 1996 Jul;179(3):254–259. doi: 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  19. Marshall C. J. Protein prenylation: a mediator of protein-protein interactions. Science. 1993 Mar 26;259(5103):1865–1866. doi: 10.1126/science.8456312. [DOI] [PubMed] [Google Scholar]
  20. Marshall C. J. Ras effectors. Curr Opin Cell Biol. 1996 Apr;8(2):197–204. doi: 10.1016/s0955-0674(96)80066-4. [DOI] [PubMed] [Google Scholar]
  21. Marshall M. S. Ras target proteins in eukaryotic cells. FASEB J. 1995 Oct;9(13):1311–1318. doi: 10.1096/fasebj.9.13.7557021. [DOI] [PubMed] [Google Scholar]
  22. Nagase T., Kawata S., Tamura S., Matsuda Y., Inui Y., Yamasaki E., Ishiguro H., Ito T., Matsuzawa Y. Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation. Int J Cancer. 1996 Mar 1;65(5):620–626. doi: 10.1002/(SICI)1097-0215(19960301)65:5<620::AID-IJC11>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  23. Nagasu T., Yoshimatsu K., Rowell C., Lewis M. D., Garcia A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 1995 Nov 15;55(22):5310–5314. [PubMed] [Google Scholar]
  24. Nassar N., Horn G., Herrmann C., Scherer A., McCormick F., Wittinghofer A. The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature. 1995 Jun 15;375(6532):554–560. doi: 10.1038/375554a0. [DOI] [PubMed] [Google Scholar]
  25. Phan T., McLeod J. G., Pollard J. D., Peiris O., Rohan A., Halpern J. P. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry. 1995 May;58(5):625–628. doi: 10.1136/jnnp.58.5.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pérez-Sala D., Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun. 1994 Mar 30;199(3):1209–1215. doi: 10.1006/bbrc.1994.1359. [DOI] [PubMed] [Google Scholar]
  27. Rodenhuis S., Boerrigter L., Top B., Slebos R. J., Mooi W. J., van't Veer L., van Zandwijk N. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol. 1997 Jan;15(1):285–291. doi: 10.1200/JCO.1997.15.1.285. [DOI] [PubMed] [Google Scholar]
  28. Tamanoi F. Inhibitors of Ras farnesyltransferases. Trends Biochem Sci. 1993 Sep;18(9):349–353. doi: 10.1016/0968-0004(93)90072-u. [DOI] [PubMed] [Google Scholar]
  29. Veerkamp J. H., Smit J. W., Benders A. A., Oosterhof A. Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. Biochim Biophys Acta. 1996 Apr 12;1315(3):217–222. doi: 10.1016/0925-4439(95)00122-0. [DOI] [PubMed] [Google Scholar]
  30. Wittinghofer A., Herrmann C. Ras-effector interactions, the problem of specificity. FEBS Lett. 1995 Aug 1;369(1):52–56. doi: 10.1016/0014-5793(95)00667-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES